ClinicalTrials.gg
Status unknownNCT05015127Updated Feb 23, 2022

A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease

A Phase 2/3 interventional study of HBM9161 680 mg qw by q2w from week 13 and Placebo in Thyroid Ophthalmopathy, sponsored by Harbour BioMed (Guangzhou) Co. Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-23.

Sponsored by Harbour BioMed (Guangzhou) Co. Ltd. · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.

Planned enrollment
36th of 45
36 · median 64
Started
2021
with 4 others
Phase 2/3
3 of 55
none open now
Registered
12th of 55
by date

Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 36th largest by planned enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2021, is one of 3 in phase 2/3, and was the 12th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Graves Ophthalmopathy with a site in China, or all of them as a file.
02

Study summary

Primary Objective: To preliminarily evaluate the efficacy of the treatment regimen of HBM9161 680 mg administered subcutaneously weekly and sequentially every other week for 12 weeks in Chinese patients with active moderate to severe TED.

Read the detailed description

This is a multicenter, randomized, double-blind and placebo-controlled study. The investigational drug is HBM9161 injection, with the indication of TED. Subjects will be randomized to treatment group I, treatment group II, or placebo group. Subjects in treatment group 1 will receive HBM9161 680 mg subcutaneously once weekly (qw) for 12 doses; Subjects in treatment group 2 will receive HBM9161 680 mg subcutaneously once weekly (qw) for 6 doses, followed by HBM9161 680 mg subcutaneously once every two weeks (q2w) for 3 doses; Subjects in placebo group will receive placebo subcutaneously once weekly (qw) for 12 doses. After the 12-week dosing period, there will be a 5-week follow-up period.

03

Conditions studied

  • Thyroid Ophthalmopathy

Browse trials for

Keywords

  • TED
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written form.
  2. Male or female between the ages of 18 and 70 (including boundary values).
  3. Active TED associated with a clinical diagnosis of Graves' disease or Hashimoto's thyroiditis with CAS ≥ 3 at the screening visit and baseline (both on a 7-item scale) in the eye with the most severe proptosis.
  4. The active period of TED starts within 9 months prior to screening visit
  5. Positive anti-TSHR antibody at screening visit.
  6. Subject is willing and able to receive treatment and complete corresponding assessments as required by the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Other uncontrolled concurrent diseases
  2. Serious TED requiring surgery or radiotherapy
  3. Suffer from diseases or ophthalmic conditions other than TED that, in the opinion of the investigator, would impact the assessment of the study drug
  4. No significant laboratory abnormalities
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    HBM9161 680 mg qw by q2w from week 13

    Subcutaneous injection; HBM9161 680 mg qw from week 13

    Drug: HBM9161 680 mg qw by q2w from week 13

  • Experimental
    HBM9161 680 mg qw by q2w from week 7

    Subcutaneous injection; HBM9161 680 mg qw by q2w from week 7

    Drug: HBM9161 680 mg qw by q2w from week 7

  • Experimental
    Placebo

    Subcutaneous injection; Placebo

    Drug: Placebo

  • Experimental
    Placebo qw by HBM9161 680mg qw from week 12

    Placebo qw by HBM9161 680mg qw from week 12

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Proptosis responder rates of the treatment groups and placebo group at Week 12

    Proptosis responder rates of the treatment groups and placebo group at Week 12

    Time frame: At week 12

Secondary outcomes

  1. The percentage of subjects with a CAS value of 0 or 1 in the study eye

    The percentage of subjects with a CAS value of 0 or 1 in the study eye

    Time frame: At week 6, week 12, week 18 and week 24

  2. The change from Baseline in proptosis measurement in the study eye

    The change from Baseline in proptosis measurement in the study eye

    Time frame: At week 6, week 12, week 18 and week 24

  3. Composite responder rate

    Composite responder rate

    Time frame: At week 6, week 12, week 18 and week 24

  4. Diplopia response rate

    Diplopia response rate

    Time frame: At week 6, week 12, week 18 and week 24

  5. The change from baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire visual function score and psychosocial function score

    The change from baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire visual function score and psychosocial function score

    Time frame: At week 6, week 12, week 18 and week 24

  6. The changes in proptosis responder rate over time

    The changes in proptosis responder rate over time

    Time frame: From week 1 to week 24

  7. The change from baseline in quantitative measurement of orbital structures by MRI, including exophthalmos values, fatty tissue thickness of inner side in eye balls, thickness of extraocular muscles. All the above parameters will be measured in millimeter

    The change from baseline in quantitative measurement of orbital structures by MRI, including exophthalmos values, fatty tissue thickness of inner side in eye balls, thickness of extraocular muscles. All the above parameters will be measured in millimeter

    Time frame: At week 12, week 24

07

Study locations

1 of 1 sites recruiting
  • Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200011, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for Oct 2022, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2021
First posted
Aug 20, 2021
StartActual
Sep 22, 2021
Primary completionEst.
Oct 2022
CompletionEst.
Dec 2022
Last update
Feb 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05015127
Lead sponsor
Harbour BioMed (Guangzhou) Co. Ltd.
Responsible party
Sponsor
First posted
Aug 20, 2021
Start date
Sep 22, 2021
Primary completion
Oct 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Feb 23, 2022

Study contacts

Huifang Zhou
Contact
fangzzfang@163.com
+86 13661901886
Jing Sun
Contact
sophiasj@126.com
+86 18516204866
Huifang Zhou
principal investigator · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion